Scinai Immunotherapeutics Ltd. Statistics
Share Statistics
Scinai Immunotherapeutics Ltd. has 853.00K shares outstanding. The number of shares has increased by -80.76% in one year.
| Shares Outstanding | 853.00K |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 44.09% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 833.81K |
| Failed to Deliver (FTD) Shares | 135 |
| FTD / Avg. Volume | 0.49% |
Short Selling Information
The latest short interest is 1.79K, so 0.21% of the outstanding shares have been sold short.
| Short Interest | 1.79K |
| Short % of Shares Out | 0.21% |
| Short % of Float | 0.22% |
| Short Ratio (days to cover) | 0.09 |
Valuation Ratios
The PE ratio is -0.37 and the forward PE ratio is null.
| PE Ratio | -0.37 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -0.52 |
| P/FCF Ratio | -0.24 |
| PEG Ratio | n/a |
Enterprise Valuation
Scinai Immunotherapeutics Ltd. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of -4.24.
| Current Ratio | 3.06 |
| Quick Ratio | 3.06 |
| Debt / Equity | -4.24 |
| Total Debt / Capitalization | 130.87 |
| Cash Flow / Debt | -0.48 |
| Interest Coverage | 30646.69 |
Financial Efficiency
Return on equity (ROE) is 1.42% and return on capital (ROIC) is -60.75%.
| Return on Equity (ROE) | 1.42% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -60.75% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -209.68K |
| Employee Count | 31 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -54.84% in the last 52 weeks. The beta is 2.46, so Scinai Immunotherapeutics Ltd.'s price volatility has been higher than the market average.
| Beta | 2.46 |
| 52-Week Price Change | -54.84% |
| 50-Day Moving Average | 3.44 |
| 200-Day Moving Average | 3.96 |
| Relative Strength Index (RSI) | 51.25 |
| Average Volume (20 Days) | 27.61K |
Income Statement
In the last 12 months, Scinai Immunotherapeutics Ltd. had revenue of $0 and earned -$6.50M in profits. Earnings per share was $-16.64.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -9.71M |
| Net Income | -6.50M |
| EBITDA | -9.19M |
| EBIT | - |
| Earnings Per Share (EPS) | -16.64 |
Balance Sheet
The company has $4.87M in cash and $20.56M in debt, giving a net cash position of -$15.69M.
| Cash & Cash Equivalents | 4.87M |
| Total Debt | 20.56M |
| Net Cash | -15.69M |
| Retained Earnings | -122.33M |
| Total Assets | 12.26M |
| Working Capital | 225.00K |
Cash Flow
In the last 12 months, operating cash flow was -$9.38M and capital expenditures -$637.00K, giving a free cash flow of -$10.02M.
| Operating Cash Flow | -9.38M |
| Capital Expenditures | -637.00K |
| Free Cash Flow | -10.02M |
| FCF Per Share | -25.65 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
SCNI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -502.72% |
| FCF Yield | -354.32% |
Analyst Forecast
Currently there are no analyst rating for SCNI.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 21, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | May 21, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -14.55 |
| Piotroski F-Score | 4 |